AzTrials
AzTrials

InfectionPhase 4LDAWB-2001NCT00176124

Leukocyte Depletion of Autologous Whole Blood

A Phase 4 study testing leukocyte depletion of whole blood and Leukocyte filtration/Depletion in people with Infection and Bacterial Infection, run by Heidelberg University at 3 sites in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Infection, Bacterial Infection, Sepsis
What is being tested?
leukocyte depletion of whole blood and Leukocyte filtration/Depletion
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,089 participants
Where
3 sitesGermany
Study dates
Apr 2001to Sep 2005
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • ASA I-III,
  • Age 18-85 years,
  • Body weight 50-125 kg
  • If female, with either a history of an accepted method of anticonception for at least 3 month prior and 1 month following the termination of the study or climacteric or with a negative betA- HCG-Test in urine or serum.
  • Preoperative blood donation of at least 2 units (450mL whole blood)
  • Preoperative hemoglobin level > 10 mg/dL
  • Able and willing to sign informed consent

Who cannot join

  • Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP 36-43).
  • systemic infection
  • acute bacterial or viral diseases
  • anemia (Hb > 11g/dL)
  • myocardial infarction within the past 6 month,
  • instable angina pectoris
Show all 19Show fewer
  • vascular stenosis (i.e. of the coronary or internal carotid arteries)
  • hemodynamic relevant valvular stenosis
  • heart failure > NYHA II
  • history of strokes or TIA
  • steroid therapy,
  • immune deficiency,
  • hematological or endocrinological disease,
  • coagulopathy,
  • history of organ transplantation,
  • simultaneous participation in a second study
  • pregnancy
  • membership at Jehovah's Witnesses
  • intended use of a cell saver

Trial locations and contacts

3 sites in 1 country.

Germany3 sites
  • Klinikum Garmisch Partenkirchen

    Garmisch-Partenkirchen, Bavaria, 82467

  • Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine MAnnheim, University of Heidelberg, Germany

    Mannheim, Baden-Wurttemberg, 68167

  • Institute of Transfusion Medicine and Hemostasiology, University of MArburg

    Marburg, 35043

Other trials in Germany

About this study

Official title: Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients

Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate

Read the detailed description

Informed Consent Form:

Prior to the first blood donation, in- and exclusion criteria should be tested. Then the patient is to inform by the investigator about the studies aim and participation conditions such as methods, risks, assurance, data security, etc. The patient and the investigator should sign the informed consent form.

Randomization:

If all inclusion criteria are well given and exclusion criteria are absent, the patient could be enrolled and randomized, prior to the first PAD. Enrollment is parallel in all centers until the final number of 1088 is reached. Breaking the seal of the provided randomization envelope with computerized randomization codes completes randomization. Time and date should be noted.

Blinding:

Randomization is done by the investigator, which should manage the blood donation. The blood bags after inline leukocyte depletion prior to storage do not look different from not depleted bags and are labeled only with the patient's identity and the subjects ID. The allocation to the group is to keep secret from patient, surgeon and anesthesiologist.

Treatment:

A PAD:

Group 1 Preoperative Donation of multiple units ( more than 2) 450 mL autologous whole blood and storage without leukocyte depletion Usual criteria and methods of PAD are used according to regional guidelines of blood donations in the respective center.

Group 2 Preoperative Donation of multiple units (more than 2) 450 mL autologous whole blood and storage following leukocyte depletion 2 to 4 hours after whole blood donations, the whole blood bags should be in-line filtered by the use of leukocyte filtration sets (provided by Pall Medical Company). Storage as in group 1 at 4 degree C in a blood fridge.

A as proposal, the Mannheim concept reveals a 95 percent security in avoidance of allogenic transfusions for a blood loss of 20-25 ml per kg body weight: Intended are 3 donations in weekly intervals. If Hb plasma con-tent decreases below 11 g/dL, the donation will be postponed to the fol-lowing week. Surgery is at the fifth week after the first donation.

B Anesthesia and Surgery:

As usual in the center, and without a difference between the two groups anesthesia and surgery should be performed under following aspects:

  • At hospital admission, the actual history should be taken, study measures (Appendix 1) and screening laboratory should be withdrawn prior to anesthesia to compute the infection risk assessment of the respective patient 13.
  • Both general and regional (spinal or epidural anesthesia) can be performed
  • Normothermia of the patients is essential to the infection rate, hypothermia increases the infection rate by every degree! The intra- and postoperative core temperature range will be requested.
  • Circulatory monitoring should be performed according to the centers conventions. Monitoring with a 5 channel ECG is suggested. Normovolemia is essential because hypovolemia is related to increased infection rate by hypoperfusion of the wound14-16. Therefore, a central venous catheter is useful but not obligatory, but urine output is required since it is a more sensitive volume indicator in absence of significant heart and renal failure (and common practice in hip surgery). An arterial line is not obligatory required.
  • Bladder catheter (Urine production more than 1ml/kg KG/h)
  • Cell Savers and hemodilution (iso- or hypervolemic) are not accepted.
  • Blood loss is to calculate carefully by subtracting rinsing from suction volumes and weighing sponges and drapes intraoperatively. Postoperatively the drainage volumes are sufficient if not massive expansion of thighs or hip occurs ( however, this should be noted as AE).
  • In the case that allogenic transfusion is required additionally, this should be leukodepleted.
  • Intra- und postoperative transfusion trigger are similar for autologous and allogenic transfusion:
  • Hb greater than 8,5 plus minus 0,5
  • HF over 100 plusminus 10 /min or 35% above base line
  • MAP below 60 plusminus 5 mmHg or 35% below base line
  • Stenocardia, chest pain
  • ST-segment changes greater than 0,2 ms

Further documentation of

  • ASA
  • sex
  • weight
  • height
  • Anesthesia duration
  • OP-duration
  • Blood loss(intra- and postoperatively)
  • Lowest diastole. RR intraoperatively as well as postoperatively POD 0
  • Time of transfusions
  • Time of urine catheter withdrawal Infection-Monitoring

Parameter:

  • Skin inspection

Criteria of wound infection:

  • secretion clear or pus,
  • pos. bacterial culture,
  • erythema
  • Urine culture if indicated by sediment (at withdrawl of bladder cathe-ter, discolored urine or fever)
  • Blood culture (if fever above 39°C after POD2)
  • Tracheal secretion (if expectoration is prutride or radiological indica-tion of bronchopneumonia)
  • Antibiotic treatment, duration, amounts, multidrug use

Woundhealing and the occurrence of infections were classified with the ASEPSIS score: Of influence is the duration of antibiotic treatment, drainage of pus, wound de-bridements, erythema, involvement of deeper tissue layers, identification of bacteria, LOS above 14 days 17.

Infection Definition

Occurrence of any infection is defined as

  • Elevation of patient's temperature/fever above 38°C on POD 3 or later or
  • Leukocytosis above the cut off point (generated for every individual subject )or
  • BSG / CRP above the cut off point (generated for every individual subject ) or
  • Isolation of bacteria from any fluid including pus or
  • Abscess (verificated by surgical drainage or ultrasonographically guided aspiration of pus ) or
  • Arthritis by local clinical symptoms and surgical drainage

Wound infection is assessed by the ASEPSIS score

Urinary tract infection is defined as

  • new isolated occurrence of leukocytosis, and/or nitrite, and/or protein or
  • isolation of bacteria more than 10 000/µl (sediment) or
  • growth of more than 100 000 colonies of a single organism in the culture

Respiratory airway infection is defined as

  • positive x-ray (chest infiltrate) and fever or
  • dyspnea or cough or purulent sputum and fever or
  • isolation of bacteria in tracheal secretion (only intubated subjects) and fever

Septicemia is defined as

  • clinical symptoms and positive blood culture
Being tested
leukocyte depletion of whole blood, Leukocyte filtration/Depletion
Keywords
leukocyte depletion, autologous transfusion,, infection, bacterial infection, sepsis, antibiotics
Medical subject headings
Infections, Bacterial Infections, Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • leukocyte depletion of whole bloodProcedure or surgery

  • Leukocyte filtration/DepletionOther

    Also called Fresenius leukocyte depletion whole blood filters

    leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours

Study groups in NCT00176124
Study groupRoleWhat they receive
1No interventionstorage and transfusion of autologous whole blood without leukocyte depletion : Control group
Receives: Procedure: leukocyte depletion of whole blood
2Experimentalstorage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
Receives: Procedure: leukocyte depletion of whole blood; Other: Leukocyte filtration/Depletion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay

    Measured: 90 days

Secondary outcomes (1)
  1. Blood loss and transfusion rate

    Measured: 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2005 (estimated)
  2. Study startApr 2001
  3. Primary completionApr 2005
  4. Study completionSep 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,089 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00176124
Sponsor's protocol ID
UniKlinMa-TF-2001-1
Other IDs
ISRCTN 99578441
Acronym
LDAWB-2001
Status last verified
Jun 2008
First submitted
11 Sep 2005
Last updated
10 Jun 2008
Results posted
No
Data monitoring committee
Yes

Publications

  • Byrne DJ, Malek MM, Davey PG, Cuschieri A. Postoperative wound scoring. Biomed Pharmacother. 1989;43(9):669-73. doi: 10.1016/0753-3322(89)90085-1.

    PubMed 2696565
  • Frietsch T, Fessler H, Kirschfink M, Nebe T, Waschke KF, Lorentz A. Immune response to autologous transfusion in healthy volunteers: WB versus packed RBCs and FFP. Transfusion. 2001 Apr;41(4):470-6. doi: 10.1046/j.1537-2995.2001.41040470.x.

    PubMed 11316896
  • Frietsch T, Krombholz K, Tolksdorf B, Nebe T, Segiet W, Lorentz A. Cellular immune response to autologous blood transfusion in hip arthroplasty: whole blood versus buffy coat-poor packed red cells and fresh-frozen plasma. Vox Sang. 2001 Oct;81(3):187-93. doi: 10.1046/j.1423-0410.2001.00107.x.

    PubMed 11703863
  • Lorentz A, Osswald PM, Schilling M, Jani L. [A comparison of autologous transfusion procedures in hip surgery]. Anaesthesist. 1991 Apr;40(4):205-13. German.

    PubMed 2058822
  • Tolksdorf B, Frietsch T, Quintel M, Kirschfink M, Becker P, Lorentz A. Humoral immune response to autologous blood transfusion in hip surgery: whole blood versus packed red cells and plasma. Vox Sang. 2001 Oct;81(3):180-6. doi: 10.1046/j.1423-0410.2001.00106.x.

    PubMed 11703862
  • Frietsch T, Lorentz A. Predonation of autologous blood is jeopardized by new regulations. Eur J Anaesthesiol. 2001 Oct;18(10):629-31. doi: 10.1046/j.1365-2346.2001.00997.x. No abstract available.

    PubMed 11553239

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing leukocyte depletion of whole blood and Leukocyte filtration/Depletion in people with Infection and Bacterial Infection, run by Heidelberg University at 3 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jun 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay (time frame: 90 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00176124, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in